Belite Bio, Inc. has initiated a rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, a novel oral therapy aimed at treating Stargardt disease type 1 (STGD1), a rare inherited retinal disorder linked to ABCA4 gene mutations. The company expects to complete this submission by the second quarter of 2026. Previously granted Breakthrough Therapy Designation, tinlarebant represents a significant advancement, as it could become the first approved treatment for STGD1, a progressive condition that typically leads to legal blindness in affected individuals.

The significance of this development lies in tinlarebant’s mechanism of action, which targets the accumulation of vitamin A-based toxins (bisretinoids) that contribute to retinal degeneration. By modulating levels of serum retinol binding protein 4 (RBP4), tinlarebant effectively reduces the transport of retinol to the eye, thereby decreasing bisretinoid formation. This approach not only addresses STGD1 but may also have implications for other retinal diseases such as geographic atrophy (GA), a form of advanced dry age-related macular degeneration (AMD). The promising results from the Phase 3 DRAGON trial bolster the therapeutic potential of this candidate.

The takeaway from Belite’s progress is a potential shift in the treatment landscape for inherited retinal disorders. If approved, tinlarebant could set a new benchmark for future research and drug development in this area, influencing timelines for similar therapeutics targeting retinal diseases. This advancement underscores the importance of innovative approaches in addressing unmet medical needs within the field of degenerative retinal diseases, ultimately aiming to improve patient outcomes and quality of life.

Source: globenewswire.com